CAR T‐cell therapy in large B cell lymphoma

Abstract CD19‐targeted chimeric antigen receptor (CAR) T‐cells have revolutionized the treatment of lymphoid malignancies, including large B cell lymphoma (LBCL). Following seminal early phase multicenter clinical trials published between 2017 and 2020, three CD19‐CAR T‐cell products received FDA and EMA approval designations in lymphoma in the third‐line setting, paving the way for follow‐up studies in the second‐line. Meanwhile, investigations into the applications of CAR T‐cell therapy have further broadened to treating high‐risk patients even prior to completion of first‐line conventional chemo‐immunotherapy. Furthermore, as early trials excluded patients with central nervous system involvement with lymphoma, several studies have recently shown promising efficacy of CD19‐CAR T‐cells in primary and secondary CNS lymphoma. Here we provide a detailed overview on clinical data supporting the use of CAR T‐cells in patients with LBCL.